Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery

被引:16
作者
Paik, E. Sun [1 ]
Lee, Yoo-Young [1 ]
Shim, Minhee [1 ]
Choi, Hyun Jin [1 ]
Kim, Tae-Joong [1 ]
Choi, Chel Hun [1 ]
Lee, Jeong-Won [1 ]
Kim, Byoung-Gie [1 ]
Bae, Duk-Soo [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Dept Obstet & Gynecol, Samsung Med Ctr, 81 Irwon Ro, Seoul 135710, South Korea
关键词
neoplasms; ovarian neoplasms; prognosis; recurrence; residual; METASTATIC MUCINOUS ADENOCARCINOMAS; CHEMOTHERAPY; SURVIVAL; STATISTICS; PREDICTORS; RESECTION; RISK;
D O I
10.1111/ajo.12529
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveThe aim of this study was to analyse patterns and timing of recurrence and their association with clinical outcomes in recurrent epithelial ovarian cancer (EOC) patients with no gross residual disease after primary debulking surgery (PDS). MethodsThis study was conducted on 303 EOC patients with no residual disease after PDS who were treated at the Samsung Medical Center from 2002 to 2012. By reviewing electronic medical records, information on date of clinical/pathological recurrence and pattern of disease presentation for each relapse were retrieved. ResultsWithin a median follow-up of 53 months (range 3-156), 88 recurrences (29.0%) and 28 cancer-related deaths (9.2%) were observed. Most of the recurrences were distant, discrete and transcoelomic. After complete cytoreduction, the initial stage was associated with location of recurrence, but not with recurrence patterns. Complete cytoreduction reduced the number of recurrences, but it did not affect timing of recurrence. In multivariate analysis for overall survival (OS), patients with distant recurrence, diffuse carcinomatosis and mixed spread pattern of transcoelomic, lymphatic and haematogenous recurrence were found to have higher risk. ConclusionsWe found that timing of recurrence was not affected by complete cytoreduction. Location, type and pattern of recurrence were also significant prognostic factors for OS, in addition to known prognostic predictors such as platinum sensitivity.
引用
收藏
页码:639 / 647
页数:9
相关论文
共 50 条
[41]   Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer [J].
Bian, Ce ;
Yao, Kui ;
Li, Li ;
Yi, Tao ;
Zhao, Xia .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2016, 293 (01) :163-168
[42]   Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer [J].
Kim, Se Ik ;
Lee, Eun Ji ;
Lee, Maria ;
Chung, Hyunhoon ;
Kim, Jae-Weon ;
Park, Noh Hyun ;
Song, Yong-Sang ;
Kim, Hee Seung .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (12) :1943-1950
[43]   Surgery in Recurrent Epithelial Ovarian Cancer: Benefits on Survival for Patients With Residual Disease of 0.1-1 cm After Secondary Cytoreduction [J].
Tian, Wen-Juan ;
Jiang, Rong ;
Cheng, Xi ;
Tang, Jie ;
Xing, Yan ;
Zang, Rong-Yu .
JOURNAL OF SURGICAL ONCOLOGY, 2010, 101 (03) :244-250
[44]   Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery [J].
Hosono, Satoyo ;
Kajiyama, Hiroaki ;
Mizuno, Kimio ;
Sakakibara, Katsumi ;
Matsuzawa, Katsuji ;
Takeda, Akihiro ;
Kawai, Michiyasu ;
Nagasaka, Tetsuro ;
Kikkawa, Fumitaka .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2011, 16 (05) :524-532
[45]   Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer [J].
Rutten, M. J. ;
Boldingh, J. H. L. ;
Schuit, E. ;
Trum, H. ;
van Driel, W. ;
Mol, B. W. J. ;
Kenter, G. G. ;
Buist, M. R. .
GYNECOLOGIC ONCOLOGY, 2014, 135 (01) :13-18
[46]   Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer [J].
Singh, Sareena ;
Guetzko, Megan ;
Resnick, Kimberly .
GYNECOLOGIC ONCOLOGY, 2016, 143 (02) :241-245
[47]   Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer [J].
Tseng, Jill H. ;
Cowan, Renee A. ;
Afonso, Anoushka M. ;
Zhou, Qin ;
Iasonos, Alexia ;
Ali, Narisha ;
Thompson, Errika ;
Sonoda, Yukio ;
O'Cearbhaill, Roisin E. ;
Chi, Dennis S. ;
Abu-Rustum, Nadeem R. ;
Roche, Kara Long .
GYNECOLOGIC ONCOLOGY, 2018, 151 (02) :287-293
[48]   Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection [J].
Gill, Sarah E. ;
McGree, Michaela E. ;
Weaver, Amy L. ;
Cliby, William A. ;
Langstraat, Carrie L. .
GYNECOLOGIC ONCOLOGY, 2017, 144 (02) :266-273
[49]   Is increased chronological age a contraindication to debulking surgery for elderly patients with advanced ovarian cancer? [J].
Park, Soo Jin ;
Mun, Jaehee ;
Yim, Ga Won ;
Lee, Maria ;
Chung, Hyun Hoon ;
Kim, Jae Weon ;
Park, Noh Hyun ;
Song, Yong Sang ;
Kim, Hee Seung .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 42 (07) :3254-3259
[50]   Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis [J].
Chiofalo, Benito ;
Bruni, Simone ;
Certelli, Camilla ;
Sperduti, Isabella ;
Baiocco, Ermelinda ;
Vizza, Enrico .
MINERVA MEDICA, 2019, 110 (04) :330-340